BIOMAT Database Logo BIOMAT Database Logo

Water-soluble pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as human A₃ adenosine receptor antagonists. 2012

Pier Giovanni Baraldi, and Giulia Saponaro, and Romeo Romagnoli, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Allan R Moorman, and Sandro Cosconati, and Salvatore Di Maro, and Luciana Marinelli, and Stefania Gessi, and Stefania Merighi, and Katia Varani, and Pier Andrea Borea, and Delia Preti
Dipartimento di Scienze Farmaceutiche, Università di Ferrara, 44100 Ferrara, Italy. baraldi@unife.it

A relevant problem of the pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine nucleus, an attractive scaffold for the preparation of adenosine receptor antagonists, is the low water solubility. We originally functionalized the C(5) position with a salifiable 4-pyridylcarbamoyl moiety that conferred good water solubility at low pH (<4.0) but poor solubility at physiologic pH, indicative of the dissociation of the pyridinium species. Here we replaced the pyridin-4-yl moiety with a 1-(substituted)piperidin-4-yl ring to exploit the higher basicity of this nucleus and for the the possibility to generate stable, water-soluble salts. The hydrochloride salt of the 1-(cyclohexylmethyl)piperidin-4-yl derivative (10, K(i)(hA(3)) = 9.7 nM, IC(50)(hA(3)) = 30 nM, K(i)(hA(1)/hA(3)) = 351, K(i)(hA(2A)/hA(3)) > 515, IC(50)(hA(2B)) > 5 μM) showed a solubility of 8 mg/mL at physiological pH and gave a stable aqueous system suitable for intravenous infusion. Molecular modeling studies were helpful in rationalizing the available structure-activity relationships and the selectivity profile of the new ligands.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006575 Heterocyclic Compounds, 3-Ring A class of heterocyclic compounds that include a three-ring fused structure. Both aromatic or non-aromatic ring structures are included in this category. Fused Heterocyclic Compounds, Three-Ring,Heterocyclic Cpds, 3 Ring,Three Ring Heterocyclic Compounds,3-Ring Heterocyclic Compounds,Fused Heterocyclic Compounds, Three Ring,Heterocyclic Compounds, 3 Ring
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D014508 Urea A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. Basodexan,Carbamide,Carmol

Related Publications

Pier Giovanni Baraldi, and Giulia Saponaro, and Romeo Romagnoli, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Allan R Moorman, and Sandro Cosconati, and Salvatore Di Maro, and Luciana Marinelli, and Stefania Gessi, and Stefania Merighi, and Katia Varani, and Pier Andrea Borea, and Delia Preti
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists.
January 2016, Current topics in medicinal chemistry,
Pier Giovanni Baraldi, and Giulia Saponaro, and Romeo Romagnoli, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Allan R Moorman, and Sandro Cosconati, and Salvatore Di Maro, and Luciana Marinelli, and Stefania Gessi, and Stefania Merighi, and Katia Varani, and Pier Andrea Borea, and Delia Preti
Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.
March 2007, Bioorganic & medicinal chemistry letters,
Pier Giovanni Baraldi, and Giulia Saponaro, and Romeo Romagnoli, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Allan R Moorman, and Sandro Cosconati, and Salvatore Di Maro, and Luciana Marinelli, and Stefania Gessi, and Stefania Merighi, and Katia Varani, and Pier Andrea Borea, and Delia Preti
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists.
November 1999, Journal of medicinal chemistry,
Pier Giovanni Baraldi, and Giulia Saponaro, and Romeo Romagnoli, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Allan R Moorman, and Sandro Cosconati, and Salvatore Di Maro, and Luciana Marinelli, and Stefania Gessi, and Stefania Merighi, and Katia Varani, and Pier Andrea Borea, and Delia Preti
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
March 1996, Journal of medicinal chemistry,
Pier Giovanni Baraldi, and Giulia Saponaro, and Romeo Romagnoli, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Allan R Moorman, and Sandro Cosconati, and Salvatore Di Maro, and Luciana Marinelli, and Stefania Gessi, and Stefania Merighi, and Katia Varani, and Pier Andrea Borea, and Delia Preti
Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.
June 1998, Journal of medicinal chemistry,
Pier Giovanni Baraldi, and Giulia Saponaro, and Romeo Romagnoli, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Allan R Moorman, and Sandro Cosconati, and Salvatore Di Maro, and Luciana Marinelli, and Stefania Gessi, and Stefania Merighi, and Katia Varani, and Pier Andrea Borea, and Delia Preti
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines to develop functionalized ligands to target adenosine receptors: fluorescent ligands as an example.
July 2019, MedChemComm,
Pier Giovanni Baraldi, and Giulia Saponaro, and Romeo Romagnoli, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Allan R Moorman, and Sandro Cosconati, and Salvatore Di Maro, and Luciana Marinelli, and Stefania Gessi, and Stefania Merighi, and Katia Varani, and Pier Andrea Borea, and Delia Preti
Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines.
February 2009, Bioorganic & medicinal chemistry letters,
Pier Giovanni Baraldi, and Giulia Saponaro, and Romeo Romagnoli, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Allan R Moorman, and Sandro Cosconati, and Salvatore Di Maro, and Luciana Marinelli, and Stefania Gessi, and Stefania Merighi, and Katia Varani, and Pier Andrea Borea, and Delia Preti
Synthesis and electrophilic substitutions of novel pyrazolo[1,5-c]-1,2,4-triazolo[4,3-a]pyrimidines.
August 2011, Molecules (Basel, Switzerland),
Pier Giovanni Baraldi, and Giulia Saponaro, and Romeo Romagnoli, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Allan R Moorman, and Sandro Cosconati, and Salvatore Di Maro, and Luciana Marinelli, and Stefania Gessi, and Stefania Merighi, and Katia Varani, and Pier Andrea Borea, and Delia Preti
Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists.
February 2002, Journal of medicinal chemistry,
Pier Giovanni Baraldi, and Giulia Saponaro, and Romeo Romagnoli, and Mojgan Aghazadeh Tabrizi, and Stefania Baraldi, and Allan R Moorman, and Sandro Cosconati, and Salvatore Di Maro, and Luciana Marinelli, and Stefania Gessi, and Stefania Merighi, and Katia Varani, and Pier Andrea Borea, and Delia Preti
QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype.
January 2011, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!